# Targeting Genomic Instability in Lethal Neuroendocrine Prostate Cancer

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2022 · $519,628

## Abstract

PROJECT SUMMARY
 There is a crucial clinical need to identify therapeutic targets for patients with highly aggressive and lethal
prostate cancer. While chromosome instability has long been recognized as a marker of advanced prostate
cancer, our understanding of the mechanisms that induce disrupted cancer genomes (aneuploidy and DNA copy
number alterations) and how they contribute to aggressive phenotypes is limited. Recent large cohort studies
have revealed highly recurrent DNA copy number alterations (CNA) in prostate and other cancers – but the
section forces behind this conserved evolution of the cancer genome are not completely understood. In prostate
cancer, there is a wide spectrum of outcomes and of genomic instability associated aneuploidy. Organ confined,
better prognosis cases of prostate cancer are typically diploid; while therapy-resistant, poor outcome cases are
highly aneuploid. Improved androgen-targeted prostate therapies (e.g. enzalutamide and abiraterone) impact
quality of life, but tumors frequently escape therapy through mechanisms involving transdifferentiation to the
nueroendocrine prostate cancer (NEPC) subtype. NEPC is highly aggressive, and thus there is a vital need to
better understand the biology and therapeutic vulnerabilities of this subtype.
 The contribution of DNA copy number alterations to driving aggressive cancer phenotypes is insufficiently
understood. Here we propose a systematic study to use integrated omics to identify genes and mutations
associated with chromosome instability and test their roles in an experimental model of NEPC prostate cancer.
Our project is centered on the hypothesis that in sum, activating oncogene mutations, tumor suppressor gene
loss, and more subtle but accumulative coordinate changes in CNA patterns are each contributing to aggressive
cancer phenotypes. We will use our prostate transformation model to test this hypothesis by altering the balance
between strong oncogene contributions and CNA-based contributions, enabled by genomic instability, and
testing the aggressive phenotypes of the resulting tumors. We anticipate that by increasing the role of genomic
instability, we will develop model systems that more closely resemble the human disease. We will thus use our
model as a pre-clinical testing ground for determining if the genes promoting or enabling genomic instability are
Achilles’ heels that can be therapeutically targeted.
 Our project is part of a newer movement to expand the molecular classification of tumors to include the
underlying mechanisms of genomic instability, and to understand how linkage-constrained refinement of the
genome can contribute to aggressive tumor phenotypes. The complexity of how tumor evolution optimizes
linkage-constrained copy number changes is a robust fit to a systems biology approach. Our project will leverage
the cancer biology and modeling expertise of the Witte lab with the cancer systems biology expertise of the
Graeber lab.

## Key facts

- **NIH application ID:** 10405055
- **Project number:** 5R01CA222877-05
- **Recipient organization:** UNIVERSITY OF CALIFORNIA LOS ANGELES
- **Principal Investigator:** THOMAS G GRAEBER
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $519,628
- **Award type:** 5
- **Project period:** 2018-06-06 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10405055

## Citation

> US National Institutes of Health, RePORTER application 10405055, Targeting Genomic Instability in Lethal Neuroendocrine Prostate Cancer (5R01CA222877-05). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10405055. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*